Prognostic and Treatment Characteristics of Metastatic KRAS G12C Mutant NSCLC

被引：0
|
作者：
Elegbede, A. [1 ]
Ezeife, D. [2 ]
Gibson, A. [1 ]
Dean, M. [1 ]
Petersen, L. [1 ]
Bebb, G. [1 ]
机构：
[1] Univ Calgary, Cumming Sch Med, Calgary, AB, Canada
[2] Tom Baker Canc Clin, Med Oncol, Calgary, AB, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
Brain metastasis; Gender; KRAS mutant NSCLC survival;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P59.25
引用
收藏
页码：S1159 / S1160
页数：3
相关论文
共 50 条
  • [41] Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC
    Burns, Timothy F.
    Dragnev, Konstantin
    Fujiwara, Yutaka
    Murciano-Goroff, Yonina R.
    Lee, Dae Ho
    Hollebecque, Antoine
    Koyama, Takafumi
    Cassier, Philippe
    Italiano, Antoine
    Heist, Rebecca S.
    Han, Ji-Youn
    Deming, Dustin
    Spira, Alexander
    Sabari, Joshua
    Chisamore, Michael J.
    Fink, Aaron
    Chen, Aaron
    Willard, Melinda D.
    Oxnard, Geoffrey R.
    Ammakkanavar, Natraj Reddy
    Pruthi, Aarohan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 : 137 - 138
  • [42] Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC
    Burns, Timothy F.
    Dragnev, Konstantin H.
    Fujiwara, Yutaka
    Murciano-Goroff, Yonina R.
    Lee, Dae Ho
    Hollebecque, Antoine
    Koyama, Takafumi
    Cassier, Philippe Alexandre
    Italiano, Antoine
    Heist, Rebecca Suk
    Han, Ji-Youn
    Deming, Dustin A.
    Spira, Alexander I.
    Sabari, Joshua K.
    Chisamore, Michael Jon
    Fink, Aaron Alan
    Chen, Aaron
    Willard, Melinda D.
    Oxnard, Geoffrey R.
    Ammakkanavar, Natraj Reddy
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Real-world treatment pattern and clinical outcome in Chinese NSCLC patients with KRAS G12C mutation
    Shen, L.
    Song, Z.
    Yin, Y.
    Lei, Y.
    Lu, S.
    ANNALS OF ONCOLOGY, 2024, 35
  • [44] Mechanisms of Resistance to KRAS G12C Inhibitors
    Ambrogio, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S96 - S96
  • [45] Clinical Data for KRAS G12C Inhibitors
    Kim, H. R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S95 - S96
  • [46] The promise and peril of KRAS G12C inhibitors
    Moore, Amanda R.
    Malek, Shiva
    CANCER CELL, 2021, 39 (08) : 1059 - 1061
  • [47] Oncogenic non-G12C KRAS mutations in KRAS G12C mutated lung adenocarcinomas in TRACERx and GENIE: A reservoir for intrinsic resistance to KRAS G12C inhibitors
    Marinelli, D.
    Pisegna, S.
    Giammaruco, M.
    Chesi, P.
    Mammone, G.
    Ceddia, S.
    Gazzaniga, P.
    Cortesi, E.
    Gelibter, A. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1345 - S1346
  • [48] Establishment of KRAS G12C mutant patient-derived xenograft (PDX) models for pre-clinical evaluation of KRAS G12C targeted anticancer therapy.
    Shi, Wenting
    Tang, Xuzhen
    Zhang, Jingying
    Kuang, Xinhong
    Zhang, Yan
    Wang, Jingjing
    Gu, Qingyang
    Ji, Qunsheng
    CANCER RESEARCH, 2021, 81 (13)
  • [49] Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
    Lito, Piro
    Solomon, Martha
    Hansen, Rasmus
    Li, Lian-Sheng
    Rosen, Neal
    CANCER RESEARCH, 2016, 76
  • [50] Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
    Lito, Piro
    Solomon, Martha
    Hansen, Rasmus
    Li, Lian-Sheng
    Rosen, Neal
    CANCER RESEARCH, 2016, 76
12345